Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 25Terminated 16Recruiting 13Unknown 7Withdrawn 5Active not recruiting 3No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 10Burkitt Lymphoma 9Lymphoma, Mantle-Cell 6Leukemia, Biphenotypic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Down Syndrome 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Sarcoma, Myeloid 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Complete Response 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Cytarabine × Clear all
NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Daiichi Sankyo

Phase 1/2 Active not recruiting
65 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Senti Biosciences

Phase 1 Active not recruiting
21 enrolled
MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT01840566 2025-12-03

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡